Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Puma Biotechnology (NYSEArca:PBYI), OrthoPediatrics Corp (NASDAQ:KIDS) and CareDx (NASDAQ:CDNA).
Puma Biotechnology (PBYI)
Cowen & Co. analyst Chris Shibutani reiterated a Hold rating on Puma Biotechnology yesterday and set a price target of $80. The company’s shares closed yesterday at $48.65, close to its 52-week low of $46.55.
According to TipRanks.com, Shibutani is a 4-star analyst with an average return of 9.9% and a 41.1% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Pieris Pharmaceuticals, Nektar Therapeutics, and United Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Puma Biotechnology with a $82.33 average price target.
See today’s analyst top recommended stocks >>
OrthoPediatrics Corp (KIDS)
In a report released yesterday, Matthew O’Brien from Piper Jaffray reiterated a Buy rating on OrthoPediatrics Corp, with a price target of $33. The company’s shares closed yesterday at $27.83.
According to TipRanks.com, O’Brien is a top 100 analyst with an average return of 27.3% and a 70.1% success rate. O’Brien covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Zimmer Biomet Holdings, and Merit Medical Systems.
OrthoPediatrics Corp has an analyst consensus of Strong Buy, with a price target consensus of $32.33, representing a 16.2% upside. In a report issued on August 8, BTIG also maintained a Buy rating on the stock with a $32 price target.
.
CareDx (CDNA)
Piper Jaffray analyst William Quirk reiterated a Buy rating on CareDx yesterday and set a price target of $18. The company’s shares closed yesterday at $14.97, close to its 52-week high of $16.
According to TipRanks.com, Quirk is a 5-star analyst with an average return of 18.1% and a 68.8% success rate. Quirk covers the Healthcare sector, focusing on stocks such as Accelerate Diagnostics, Pacific Biosciences, and Idexx Laboratories.
Currently, the analyst consensus on CareDx is a Moderate Buy with an average price target of $17.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
